SureTrader Stock Hero Advertisement SureTrader SPDR Advertisement
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator the submariner, Inoviorulez, pistol1p
Search This Board:
Last Post: 5/22/2015 7:33:04 AM - Followers: 92 - Board type: Free - Posts Today: 1

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.


RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.


This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...


Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
RXII News: RXi Pharmaceuticals Issues Open Letter to Shareholders 12/22/2014 07:02:00 AM
RXII News: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of En... 12/17/2014 07:02:00 AM
News News Alert: Securities Registration Statement (s-1/a) 05/22/2015 06:05:31 AM
#1762  Sticky Note FBR Capital rates RXII a "Hold" rating with Inoviorulez 04/09/15 01:56:19 PM
#1969   RXII New amendment this morning. Haven't read StockingUp333 05/22/15 07:33:04 AM
#1968   As well don't forget TANG is about The Other Guy 05/21/15 12:19:44 PM
#1967   Agree 100%. As well don't forget TANG StockingUp333 05/21/15 11:07:44 AM
#1966   This S1-flingis bullish for RXII for a few Inoviorulez 05/21/15 10:59:42 AM
#1965   $RXII now is the time for this to StockingUp333 05/21/15 10:37:29 AM
#1964   False push down to entice shorts to start The Other Guy 05/21/15 09:31:33 AM
#1963   So much for .50 holding...they really had to ashy2classy 05/21/15 09:24:00 AM
#1962   Yup...guess these going long term. the submariner 05/21/15 09:15:49 AM
#1961   A push down in pre-market. The Other Guy 05/21/15 09:09:20 AM
#1960   Interesting S-1...if they can garner the 25m that the submariner 05/21/15 07:35:36 AM
#1959   Hope the bleeding is almost done. Holding Black sunshine 05/20/15 07:56:45 PM
#1958   $PBMD was on the same boat for the oldtimerr 05/20/15 06:55:32 PM
#1957   Yep, you called it at the time. I The Other Guy 05/20/15 10:49:36 AM
#1956   Tang had about 25% to do with the decline! buddygray 05/20/15 09:59:25 AM
#1955   It's possible but I doubt the selling rate The Other Guy 05/20/15 09:44:59 AM
#1954   The other guy....since last Wednesday their have been the submariner 05/20/15 09:20:13 AM
#1953   Tang is done only if the rate of The Other Guy 05/20/15 09:09:26 AM
#1952   I agree.short squeeze might start today. alexander77 05/20/15 09:07:44 AM
#1951   My guess is Tang is done..completely liquidated since the submariner 05/20/15 08:35:02 AM
#1950   Last Wednesday TANG had 7% of the current oldtimerr 05/19/15 09:39:59 PM
#1949   It doesn't look like Tang sold any shares Inoviorulez 05/19/15 06:06:03 PM
#1948   Is TANG DONE selling? L2 shows a more oldtimerr 05/19/15 04:07:39 PM
#1947   Hasn't happened yet obviously....soon Black sunshine 05/18/15 07:03:25 PM
#1946   Still cannot see the short squeeze you mentioned. Dev851 05/18/15 02:45:54 PM
#1945   Short squeeze is coming! alexander77 05/18/15 12:44:32 PM
#1944   Ye$$$ Tang will be almost finished now! alexander77 05/18/15 09:57:49 AM
#1943   Yup....things that make you go hmmmmmm??? the submariner 05/18/15 09:56:51 AM
#1942   Wow, selling continues... ashy2classy 05/18/15 09:54:40 AM
#1941   Not my area of expertise. I bet IR The Other Guy 05/15/15 01:15:45 PM
#1940   Question:If Samcyprone can show significant benefit in Malignant alexander77 05/15/15 06:13:30 AM
#1939   Thanks, TOG! Sure hope the S1 won't kill ashy2classy 05/14/15 02:11:59 PM
#1938   Thanks for the details, OtherGuy. Btw, the full value1008 05/14/15 11:26:14 AM
#1937   Listening again to the conference call here are The Other Guy 05/14/15 10:52:01 AM
#1936   If I remember correctly..after the last Q came the submariner 05/14/15 10:21:58 AM
#1935   Good catch. Numbers should be percentage not The Other Guy 05/14/15 09:50:28 AM
#1934   From the cc yesterday, the financing is close. The Other Guy 05/14/15 09:44:51 AM
#1933   I think you have your numbers wrong. oldtimerr 05/14/15 09:41:21 AM
#1932   Yes, it will be very interesting to see value1008 05/14/15 09:36:55 AM
#1931   What ifs, it's all opinions, bears against Bulls. oldtimerr 05/14/15 09:34:44 AM
#1930   As of March 31st, Tang had 19M worth The Other Guy 05/14/15 09:20:19 AM
#1929   2.6M shares for Tang is still a lot; value1008 05/14/15 09:07:50 AM
#1928   By the end of 2016 RXII will be oldtimerr 05/13/15 10:26:03 PM
#1927   The huge spike in short interest probably came Inoviorulez 05/13/15 10:18:28 PM
#1926   Yep Tang is just about done. 2.3 million Inoviorulez 05/13/15 10:16:22 PM
#1925   Nothing indicative of a $17M market cap. The The Other Guy 05/13/15 05:40:03 PM
#1924   Positive first impression? alexander77 05/13/15 05:26:50 PM
#1923   Might have to wait until tomorrow. I plan The Other Guy 05/13/15 05:24:58 PM
#1922   Could you give an update later about the alexander77 05/13/15 05:18:36 PM
#1921   Excellent discussion in the Q&A. Both about R&D The Other Guy 05/13/15 05:16:47 PM
#1920   I'm listening. Discussing clinical trials right now. $20 The Other Guy 05/13/15 04:52:06 PM